This company listing is no longer active
Medlab Clinical Resultados de beneficios anteriores
Pasado controles de criterios 0/6
Medlab Clinical's earnings have been declining at an average annual rate of -18.9%, while the Biotechs industry saw earnings growing at 19.6% annually. Revenues have been declining at an average rate of 19.2% per year.
Información clave
-18.9%
Tasa de crecimiento de los beneficios
-7.9%
Tasa de crecimiento del BPA
| Crecimiento de la industria Biotechs | 9.6% |
| Tasa de crecimiento de los ingresos | -19.2% |
| Rentabilidad financiera | -108.3% |
| Margen neto | -541.7% |
| Última actualización de beneficios | 30 Jun 2022 |
Actualizaciones de resultados anteriores recientes
Recent updates
Shareholders May Be More Conservative With Medlab Clinical Limited's (ASX:MDC) CEO Compensation For Now
Oct 06
Is Medlab Clinical (ASX:MDC) In A Good Position To Invest In Growth?
Oct 05What We Learned About Medlab Clinical's (ASX:MDC) CEO Pay
Feb 21Medlab Clinical (ASX:MDC) Share Prices Have Dropped 69% In The Last Three Years
Dec 30
Medlab Clinical Limited (ASX:MDC) Is Expected To Breakeven In The Near Future
Nov 22Desglose de ingresos y gastosBeta
Cómo gana y gasta dinero Medlab Clinical. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 30 Jun 22 | 2 | -8 | 12 | 2 |
| 31 Mar 22 | 1 | -9 | 9 | 1 |
| 31 Dec 21 | 4 | -12 | 11 | 1 |
| 30 Sep 21 | 4 | -12 | 11 | 2 |
| 30 Jun 21 | 1 | -10 | 11 | 2 |
| 31 Mar 21 | 1 | -10 | 10 | 2 |
| 31 Dec 20 | 1 | -11 | 9 | 2 |
| 30 Sep 20 | 2 | -12 | 9 | 2 |
| 30 Jun 20 | 3 | -13 | 10 | 2 |
| 31 Mar 20 | 4 | -12 | 10 | 2 |
| 31 Dec 19 | 4 | -12 | 11 | 2 |
| 30 Sep 19 | 5 | -10 | 10 | 1 |
| 30 Jun 19 | 5 | -8 | 10 | 1 |
| 31 Mar 19 | 5 | -7 | 8 | 1 |
| 31 Dec 18 | 5 | -6 | 7 | 0 |
| 30 Sep 18 | 4 | -5 | 7 | 0 |
| 30 Jun 18 | 4 | -5 | 6 | 0 |
| 31 Mar 18 | 4 | -4 | 6 | 0 |
| 31 Dec 17 | 5 | -4 | 6 | 0 |
| 30 Sep 17 | 5 | -4 | 5 | 0 |
| 30 Jun 17 | 4 | -4 | 5 | 0 |
| 31 Mar 17 | 4 | -4 | 5 | 0 |
| 31 Dec 16 | 4 | -4 | 4 | 0 |
| 30 Sep 16 | 3 | -4 | 4 | 0 |
| 30 Jun 16 | 3 | -3 | 4 | 0 |
Ingresos de calidad: MDC is currently unprofitable.
Margen de beneficios creciente: MDC is currently unprofitable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: MDC is unprofitable, and losses have increased over the past 5 years at a rate of 18.9% per year.
Acelerando crecimiento: Unable to compare MDC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Beneficios vs. Industria: MDC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.2%).
Rentabilidad financiera
Alto ROE: MDC has a negative Return on Equity (-108.25%), as it is currently unprofitable.